[Secondary neurologic manifestations of psychotropic therapeutics. Neurophysiological approach].
D000125:Achilles Tendon / Q000502:physiology; D000928:Antidepressive Agents / Q000009:adverse effects*; D001480:Basal Ganglia Diseases / Q000139:chemically induced; D002090:Butyrophenones / Q000009:adverse effects; D003913:Dextroamphetamine / Q000009:adverse effects; D004576:Electromyography; D006801:Humans; D006993:Hypnotics and Sedatives / Q000009:adverse effects*; D009046:Motor Neurons / Q000187:drug effects; D009069:Movement Disorders / Q000139:chemically induced*; D009470:Muscle Spindles / Q000502:physiology; D009461:Neurologic Manifestations; D009476:Neurons, Efferent / Q000187:drug effects; D011930:Reaction Time; D012023:Reflex, Monosynaptic / Q000187:drug effects; D012584:Sciatic Nerve / Q000502:physiology; D013116:Spinal Cord / Q000187:drug effects; D014149:Tranquilizing Agents / Q000009:adverse effects*
D000928:Antidepressive Agents; D002090:Butyrophenones; D006993:Hypnotics and Sedatives; D014149:Tranquilizing Agents; D003913:Dextroamphetamine
Les manifestations neurologiques secondaires des thérapeutiques psychotropes. Approche neurophysiologique.